Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-76fb5796d-22dnz Total loading time: 0 Render date: 2024-04-26T13:33:51.927Z Has data issue: false hasContentIssue false

Chapter 41 - Antiphospholipid Antibody Syndrome

from Section 5 - Disorders Involving Abnormal Coagulation

Published online by Cambridge University Press:  15 June 2018

By
Christopher H. Topel  and
Robin L. Brey
Edited by
Louis Caplan  and
José Biller
Louis Caplan
Affiliation:
Beth Israel-Deaconess Medical Center, Boston
José Biller
Affiliation:
Loyola University Stritch School of Medicine, Chicago
Get access

Summary

A summary is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Chapter
Information
Uncommon Causes of Stroke , pp. 305 - 316
Publisher: Cambridge University Press
Print publication year: 2018

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Agnelli, G., Buller, H. R, Cohen, A., et al. 2013 Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med, 368, 799–808.Google Scholar
Alarcon-Segovia, D., Deleze, M., and Oria, C. V. 1989. Antiphospholipid antibodies and the antiphospholipid syndrome in systemic lupus erythematosus: A prospective analysis of 500 consecutive patients. Medicine, 68, 353–65.CrossRefGoogle ScholarPubMed
Ameri, A. and Bousser, M. G. 1992. Cerebral venous thrombosis. Neurol Clin, 10, 87–111.CrossRefGoogle ScholarPubMed
Andreoli, L., Chighizola, C. B., Banzato, A., et al. 2013. Estimated frequency of antiphospholipid antibodies in patients with pregnancy morbidity, stroke, myocardial infarction, and deep vein thrombosis: A critical review of the literature. Arthritis Care Res, 65, 1869–73.Google Scholar
Antiphospholipid Antibodies in Stroke Study (APASS) Group. 1990. Clinical and laboratory findings in patients with antiphospholipid antibodies and cerebral ischemia. Stroke, 21, 1268–73.Google Scholar
Arnout, I. 1996. The pathogenesis of antiphospholipid antibody syndrome: Hypothesis based on parallelisms with heparin-induced thrombocytopenia. Thromb Haemost, 75, 536–41.Google Scholar
Arnout, J. and Vermylen, I. 1998. Mechanism of action of beta-2-glycoprotein-1-dependent lupus anticoagulants. Lupus, 7, S23–8.Google Scholar
Arnaud, L., Mathian, A., Ruffatti, A., et al. 2014. Efficacy of aspirin for the primary prevention of thrombosis in patients with antiphospholipid antibodies: an international and collaborative meta-anaylsis. Autoimmunity Reviews, 13, 281–91.CrossRefGoogle Scholar
Asherson, R.A. 1992. The catastrophic antiphospholipid syndrome. J Rheumatol, 19, 506–12.Google Scholar
Asherson, R. and Cervera, R. 2003. Catastrophic antiphospholipid syndrome. Rheumatol Rep, 5, 395–400.CrossRefGoogle ScholarPubMed
Atsumi, T., Ieko, M., Bertolaccini, M. L., et al. 2000. Association of autoantibodies against the phosphatidylserine–prothrombin complex with manifestations of the antiphospholipid syndrome and with the presence of lupus anticoagulant. Arthritis Rheum, 43, 1982–93.3.0.CO;2-2>CrossRefGoogle ScholarPubMed
Bauer, K. A. 2013. Pros and cons of new oral anticoagulants. Hematology, 2013, 464–70.CrossRefGoogle ScholarPubMed
Bauersachs, R., Berkowitz, S. D., Brenner, B., et al. 2010. Oral rivaroxaban for symptomatic venous thromboembolism (and supplementary appendix). N Engl J Med, 363, 2499–510.Google Scholar
Belvís, R., Santamaría, A., Martí-Fàbregas, J., et al. 2007. Patent foramen ovale and prothrombotic markers in young stroke patients. Blood Coagul Fibrinolysis, 18, 537–42.Google Scholar
Bertolaccini, M. L., Amengual, O., Andreoli, L., et al. 2014. 14th International Congress on Antiphospholipid Antibodies Task Force. Report on antiphospholipid syndrome laboratory diagnostics and trends. Autoimmunity Rev, 13, 917–30.Google Scholar
Bottin, L., Frances, C., de Zuttere, D., et al. 2015. Strokes in Sneddon syndrome without antiphospholipid antibodies. Ann Neurol, 77, 817–29.Google Scholar
Boles, J. and Mackman, N. 2010. Role of tissue factor in thrombosis in antiphospholipid antibody syndrome. Lupus, 19, 370–78.Google Scholar
Brey, R. L. 2004. Management of the neurological manifestations of APS: What do the trials tell us? Thromb Res, 114, 489–99.Google Scholar
Brey, R. L., Hart, R. G., Sherman, D. G., and Tegeler, C. T. 1990. Antiphospholipid antibodies and cerebral ischemia in young people. Neurology, 40, 1190–6.CrossRefGoogle ScholarPubMed
Büller, H. R., Décousus, H., Grosso, M. A., et al. 2013. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med, 369, 1406–15.Google Scholar
Campbell, A. L., Pierangeli, S. S., Wellhausen, S., and Harris, E. N. 1995. Comparison of the effects of anticardiolipin antibodies from patients with the antiphospholipid antibody syndrome and with syphilis on platelet activation and aggregation. Thromb Haemost, 73, 529–34.Google Scholar
Carhuapoma, J. R., Mitsias, R., and Levine, S. R. 1997. Cerebral venous thrombosis and anticardiolipin antibodies. Neurology, 28, 2363–9.Google ScholarPubMed
Casciola-Rosen, L., Rosen, A., Petri, M., and Schlissel, M. 1996. Surface blebs on apoptotic cells are sites of enhanced procoagulant activity implications for coagulation events and antigenic spread in systemic lupus erythematosus. Proc Natl Acad Sci USA, 93, 1624–9.CrossRefGoogle ScholarPubMed
Cervera, R., Piette, J. C., Font, J., et al. 2002. Antiphospholipid syndrome: Clinical and immunologic manifestations and patterns of disease expression in a cohort of 1000 patients. Arthritis Rheum, 46, 1019–27.CrossRefGoogle Scholar
Cervera, R., Khamashta, M. A., Font, J., et al. 2003. Morbidity and mortality in systemic lupus erythematosus during a 10-year period: A comparison of early and late manifestations in a cohort of 1000 patients. Medicine, 82, 299–308.Google Scholar
Cervera, R., Serrano, R., Pons-Estel, G. J. et al. 2015. Morbidity and mortality in the antiphospholiid syndrome during a 10-year period: A multicenter prospective study of 1000 patients. Ann Rheum Dis, 74, 1011–18.Google Scholar
Cesbron, J. Y., Amouyel, R., and Masy, E. 1997. Anticardiolipin antibodies and physical disability in the elderly. Ann Intern Med, 126, 1003.CrossRefGoogle ScholarPubMed
Chapman, J., Abu-Katash, M., Inzelberg, R., et al. 2002. Prevalence and clinical features of dementia associated with the antiphospholipid syndrome and circulating anticoagulants. J Neurol Sci, 203–204, 81–4.Google Scholar
Chaturvedi, S., Jin, Z., Homma, S., et al., on behalf of the PICSS–APASS investigators. 2009. Patent foramen ovale, cardiac valve thickening, and antiphospholipid antibodies as risk factors for subsequent vascular events. The PICSS–APASS study. Stroke, 40, 2337–42.Google Scholar
Chinnery, P. E, Shaw, P. I., Ince, P. G., Jackson, G. H., and Bishop, R. I. 1997. Fulminant encephalopathy due to the catastrophic primary antiphospholipid syndrome. J Neurol Neurosurg Psychiatry, 62, 300–1.Google Scholar
Ciocca, R. G., Choi, J., and Graham, A. M. 1995. Antiphospholipid antibodies lead to increased risk in cardiovascular surgery. Am J Surg, 170, 198–200.Google Scholar
Cojocaru, I. M., Cojocaru, M., Burcin, C., et al. 2007. Evaluation of antiphospholipid antibodies in young women with ischemic stroke. Romanian J Int Med, 45, 201–4.Google Scholar
Crowther, M. A., Ginsberg, J. S., Julian, J., et al. 2003. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. [See comment] [erratum appears in N Engl J Med, 2003 Dec 25; 349, 2577]. N Engl J Med, 349, 1133–8.Google Scholar
de Moerloose, P., Boehlen, E., and Reber, G. 1997. Prevalence of anticardiolipin and antinuclear antibodies in an elderly hospitalized population and mortality after a 6-year follow-up. Age Aging, 27, 319–21.Google Scholar
Del Papa, N., Guidali, L., Sala, A., et al. 1997a. Endothelial cells as target for antiphospholipid antibodies. Arthritis Rheum, 40, 551–61.Google Scholar
Del Papa, N., Raschi, E., Catelli, L., et al. 1997. Endothelial cells as a target for antiphospholipid antibodies: Role of anti-beta-2-glycoprotein 1 antibodies. Am J Reprod Immunol, 38, 212–7.Google Scholar
Deschiens, M. A., Conard, J., Horellou, M. H., et al. 1996. Coagulation studies, factor V Leiden, and anticardiolipin antibodies in 40 cases of cerebral venous sinus thrombosis. Stroke, 27, 1724–30.Google Scholar
Drouvalakis, K. A. and Buchanan, T. T. C. 1998. Phospholipid specificity of autoimmune and drug induced lupus anticoagulants: Association of phos-phatidylethanolamine reactivity with thrombosis in autoimmune disease. J Rheumatol, 25, 290–5.Google Scholar
Erkan, D., Lockshin, M. D., and APS ACTION members. 2012. APS ACTION–Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking. Lupus, 21, 695–98.Google Scholar
Erkan, D., Aguiar, C. L., Andrade, D., et al., 2014. 14th International Congress on Antiphospholipid Antibodies Task Force. Report on antiphospholipid syndrome treatment trends. Autoimmunity Rev, 13, 685–96.CrossRefGoogle ScholarPubMed
Filippidis, E., Kapsalaki, G., Patramani, K., et al. 2009. Cerebral venous sinus thrombosis: Review of the demographics, pathophysiology, current diagnosis, and treatment. Neurosurgical Focus, 27, E3.Google Scholar
Galli, M., Comfurius, P., Maassen, C, et al. 1990. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet, 335, 1544–7.CrossRefGoogle Scholar
Gharavi, A. E. and Pierangeli, S. S. 1998. Origin of antiphospholipid antibodies: Induction of aPL by viral peptides. Lupus, 7, S52–4.CrossRefGoogle ScholarPubMed
Gharavi, A. E., Tang, H., Gharavi, E. E., Wilson, W. A., and Espinoza, L. R. 1995. Induction of aPL by immunization with a 15 amino acid peptide. Arthritis Rheum, 38, S296.Google Scholar
Gharavi, A. E., Tang, H., Gharavi, E. E., Espinoza, L. R., and Wilson, W. A. 1996. Induction of antiphospholipid antibodies by immunization with a viral peptide. Arthritis Rheum, 39, S319.Google Scholar
Hachulla, E., et al. 1998. Cerebral magnetic resonance imaging in patients with or without antiphospholipid antibodies. Lupus, 7, 124–31.Google Scholar
Hudson, M., Herr, A. L., Rauch, J., et al. 2003. The presence of multiple prothrombotic risk factors is associated with a higher risk of thrombosis in individuals with anticardiolipin antibodies. J Rheumatol, 30, 2385–91.Google Scholar
Hughes, G. R. V. 1983. Thrombosis, abortion, cerebral disease and lupus anticoagulant. Br Med J, 187, 1088–91.Google Scholar
Jacobson, M. W., Rappaport, L. J., Keenan, R. A., et al. 1999. Neuropsychological deficits associated with antiphospholipid antibodies. J Clin Exp Neuropsychol, 21, 251–64.Google Scholar
Janardhan, V., Wolf, P. A., Kase, C. S., et al. 2004. Anticardiolipin antibodies and risk of ischemic stroke and transient ischemic attack: the Framingham cohort and offspring study. Stroke, 35, 736–41.Google Scholar
Kalashnikova, L. A., Nasonov, E. L., Kushekbaeva, A. E., and Gracheva, L. A. 1990. Anticardiolipin antibodies in Sneddon’s syndrome. Neurology, 40, 464–7.CrossRefGoogle ScholarPubMed
Khamashta, M. A., Cuadrado, M. J., Mujic, F., et al. 1995. The management of thrombosis in the antiphospholipid antibody syndrome. N Engl J Med, 332, 993–7.Google Scholar
Klemp, P., Cooper, R. C, Strauss, F. J., et al. 1988. Anticardiolipin antibodies in ischemic heart disease. Clin Exp Immunol, 74, 254–7.Google Scholar
Krnic-Barrie, S., Reister, O., Connor, C., et al. 1997. A retrospective review of 61 patients with antiphospholipid syndrome. Arch Intern Med, 157, 2101–8.Google Scholar
Labarca, J. A., Rabaggliati, R. M., Radrigan, F. J., et al. 1997. Antiphospholipid syndrome associated with cytomegalovirus infection: case report and review of the literature. Clin Infect Dis 24, 197–200.Google Scholar
Law, G., Magder, L., Fang, H., et al., 2014. Hydroxychloroquine reduces thrombosis (both arterial and venous) in systemic lupus erythematosus, particularly in antiphospholipid positive patients. Annals of the Rheumatic Diseases, 71, 547.Google Scholar
Levine, S. R., Brey, R. L., Salowich-Palm, L., Sawaya, K. L., and Havstad, S. 1993. Antiphospholipid antibody associated stroke: Prospective assessment of recurrent event risk. Stroke, 24, 188.Google Scholar
Levine, S. R., Brey, R. L., Sawaya, K. L., et al. 1995. Recurrent stroke and thrombo-occlusive events in the antiphospholipid syndrome. Ann Neurol, 38, 119–24.CrossRefGoogle ScholarPubMed
Levine, S. R., Brey, R. L., Tilley, B. C, et al. 2004. Antiphospholipid antibodies and subsequent thrombo-occlusive events in patients with ischemic stroke. JAMA, 291, 576–84.Google Scholar
Levy, R. A., Awad, E., Olivera, J., and Porto, L. C. 1998. Placental pathology in antiphospholipid syndrome. Lupus, 7, S81–5.Google Scholar
Loizou, S., McCrea, J. D., Rudge, A. C, et al. 1985. Measurement of anticardiolipin antibodies by an enzyme linked immunosorbent assay (ELISA): Standardization and quantitation of results. Clin Exp Immunol, 62, 738–45.Google Scholar
Lopez, L. R., Dier, K. J., Lopez, D., Merrill, J. T., Fink, C. A. 2004. Beta-2-glycoprotein 1 and antiphosphatidylserine antibodies are predictors of arterial thrombosis in patients with antiphospholipid antibody syndrome. Am J Clin Pathol 121, 142–9.Google Scholar
Marlar, R. A. and Neumann, A. 1990. Neonatal purpura fulminans due to homozygous protein C or protein S deficiencies. Semin Thromb Hemost, 16, 299–309.Google Scholar
McIntyre, J. A., Wagenknecht, D. R., and Waxman, D. W. 2003. Frequency and specificities of antiphospholipid antibodies in volunteer blood donors. Immunobiol, 207, 59–63.Google Scholar
McNeil, H. P., Simpson, R. J., Chesterman, C. N., and Krilis, S. A. 1990. Antiphospholipid antibodies are directed to a complex antigen that includes a lipid-binding inhibitor of coagulation: β2-glycoprotein I (apolipoprotein H). Proc Natl Acad Sci USA, 87, 4120–4.Google Scholar
Meroni, P. L., Del Papa, N., Raschi, E., et al. 1998. β2 glycoprotein 1 as a co-factor for antiphospholipid reactivity with endothelial cells. Lupus, 7, S44–7.Google Scholar
Miyakis, S., Lockshin, M. D., Atsumi, T., et al. 2006. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost, 4, 295–306.Google Scholar
Molad, Y., Sidi, Y., Gornish, M., et al. 1992. Lupus anticoagulant: Correlation with magnetic resonance imaging of brain lesions. J Rheumatol, 19, 556–61.Google ScholarPubMed
Monroe, D. M. and Key, N. S. 2007. The tissue factor–factor VIIa complex: Procoagulant activity, regulation, and multitasking. J Thromb Haemost, 5, 1097–105.Google Scholar
Mosek, A., Yust, L., Trêves, T. A., et al. 2000 Dementia and antiphospholipid antibodies. Dement Geriatr Cogn Disord, 11, 36–8.Google Scholar
Nencini, R., Baruffi, M. C., Abbate, R., et al. 1992. Lupus anticoagulant and anticardiolipin antibodies in young adults with cerebral ischemia. Stroke, 23, 189–93.Google Scholar
Neville, C., Ruach, J., Kassis, J., et al. 2003. Thromboembolic risk in patients with high titre anticardiolipin and multiple antiphospholipid antibodies. Thromb Haemost, 90, 108–15.Google Scholar
Nojima, J., Suehisa, E., Akita, N., et al. 1997. Risk of arterial thrombosis in patients with anticardiolipin antibodies and lupus anticoagulant. Br J Haematol, 96, 447–50.Google Scholar
Nojima, J., Masuda, Y., Iwatani, Y., et al. 2008. Tissue factor expression on monocytes induced by antiphospholipid antibodies as a strong risk factor for thromboembolic complications in SLE patients. Biochem Biophys Res Commun, 365, 195–200.Google Scholar
Otomo, K., Atsumi, T., Amengual, O., et al. 2012. Efficacy of the antiphospholipid score for the diagnosis of antiphospholipid syndrome and its predictive value for thrombotic events. Arthritis Rheumatism, 64, 504–12.CrossRefGoogle ScholarPubMed
Pengo, V., Ruffatti, A., Legnani, C., et al. 2011. Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: A multicenter prospective study. Thrombosis Hemostasis, 118, 4717–18.Google Scholar
Pezzini, A., Grassi, M., Lodigiani, C., et al. 2014. Predictors of long-term recurrent vascular events after ischemic stroke at young age. The Italian project on stroke in young adults. Circulation, 129, 1668–76.Google Scholar
Pierangeli, S. S., Girardi, G., Vega-Ostertag, M., et al. 2005. Requirement of activation of complement C3 and C5 for antiphospholipid antibody-mediated thrombophilia. Arthritis Rheum, 52, 2120–4.Google Scholar
Provenzale, J. M., Heinz, E. R., Ortel, T. L., et al. 1994. Antiphospholipid antibodies in patients without systemic lupus erythematosus: Neuroradiologic findings. Radiology, 192, 531–7.Google Scholar
Rand, J. H., Wu, X. X., Andree, H. A., et al. 1997. Pregnancy loss in the antiphospholipid antibody syndrome: A possible thrombogenic mechanism. N Engl J Med, 337, 154–60.Google Scholar
Rand, J. H., Wu, X. X., Quinn, A. S., et al. 2008. Hydroxychloroquine directly reduces the binding of antiphospholipid antibody–beta2-glycoprotein I complexes to phospholipid bilayers. Blood, 112, 1687–95.CrossRefGoogle ScholarPubMed
Rosove, M. H. and Brewer, P. M. C. 1992. Antiphospholipid thrombosis: Clinical course after the first thrombotic event in 70 patients. Ann Intern Med, 117, 303–8.Google Scholar
Roubey, R. A. S. 1998. Mechanisms of autoantibody-mediated thrombosis. Lupus, 7, S114–9.Google Scholar
Saidi, S., Mahjoub, T., and Almawi, W. Y. 2009. Lupus anticoagulants and antiphospholipid antibodies as risk factors for a first episode of ischemic stroke. J Thromb Haemost, 7, 1075–80.CrossRefGoogle ScholarPubMed
Sailer, M., Burchert, W., Ehrenheim, C., et al. 1997. Positron emission tomography and magnetic resonance imaging for cerebral involvement in patients with systemic lupus erythematosus. J Neurol, 244, 186–93.Google Scholar
Schmidt, R., Auer-Grumbach, P., Fazekas, F., Offenbacher, H., and Kapeller, R. 1995. Anticardiolipin antibodies in normal subjects. Neuropsychological correlates and MRI findings. Stroke, 26, 749–54.Google Scholar
Schmidt-Tanguy, A., Voswinkel, J., Henrion, D., Subra, J., Loufrani, L., et al. 2013. Anti- thrombotic effects of hydroxychloroquine in primary antiphospholipid syndrome patients. J Thromb Haemost, 11, 1927–9.Google Scholar
Schulman, S., Kearon, C., Kakkar, A. K., et al. 2009. Dabigatran versus warfarin for the treatment of acute venous thromboembolism. N Engl Med, 361, 2341–52.Google Scholar
Sciascia, S., Cosseddu, D., Montaruli, B. et al. 2011. Risk scale for the diagnosis of antiphospholipid syndrome. Ann Rheum Dis, 70, 1517–18.Google Scholar
Sciascia, S., Sanna, G., Murru, V., et al. 2013. GAPPS: The global anti-phospholipid syndrome score. Rheumatology, 52, 1397–403.Google Scholar
Sciascia, S., Sanna, G., Khamashta, M. A., et al. 2015. The estimated frequency of antiphospholipid antibodies in young adults with cerebrovascular events: A systematic review. Ann Theum Dis, 74, 2028–33.Google ScholarPubMed
Shah, N. M., Khamashta, M. A., Atsumi, T., and Hughes, G. R. V. 1998. Outcome of patients with anticardiolipin antibodies: A 10 year follow-up of 52 patients. Lupus, 7, 3–6.Google Scholar
Shi, T., Iverson, G. M., Qi, J. C., et al. 2004. Beta 2-glycoprotein I binds factor XI and inhibits its activation by thrombin and factor XIIa: Loss of inhibition by clipped beta 2-glycoprotein I. Proc Natl Acad Sci U S A, 101, 3939 –44.Google Scholar
Sneddon, I. B. 1965. Cerebral vascular lesions in livedo reticularis. Br J Dermatol, 77, 180–5.Google Scholar
Tietjen, G. E., Day, M., Norris, L., et al. 1998. Role of anticardiolipin antibodies in young persons with migraine and transient focal neurologic events. Neurology, 50, 1433–40.Google Scholar
Toubi, E., Khamashta, M. A., Panarra, A., and Hughes, G. R. V. 1995. Association of antiphospholipid antibodies with central nervous system disease in systemic lupus erythematosus. Am J Med, 99, 397–401.Google Scholar
Tourbah, A., Peitte, J. C, Iba-Zizen, M., et al. 1997. The natural course of cerebral lesions in Sneddon syndrome. Arch Neurol, 54, 53–60.Google Scholar
Tuhrim, S., Rand, J. H., Wu, X., et al. 1999. Antiphosphatidylserine antibodies are independently associated with ischemic stroke. Neurology, 53, 1523–7.Google Scholar
Urbanus, R. T., Siegerink, B., Roest, M., et al. 2009. Antiphospholipid antibodies and risk of myocardial infarction and ischaemic stroke in young women in the RATIO study: A case-control study. Lancet Neuro, 8, 998–1005.CrossRefGoogle ScholarPubMed
van Goor, M. R, Alblas, C. L., Leebeek, E W., Koudstaal, P. J., and Dippel, D. W. 2004. Do antiphospholipid antibodies increase the long-term risk of thrombotic complications in young patients with a recent TLA or ischemic stroke? Acta Neurol Scand, 109, 410–5.Google Scholar
Vega-Ostertag, M. E., Ferrara, D. E., Romay-Penabad, Z., et al. 2007. Role of p38 mitogen-activated protein kinase in antiphospholipid antibody-mediated thrombosis and endothelial cell activation. J Thromb Haemost, 5, 1828–1834.Google Scholar
Vermylen, J., Van Geet, C, and Arnout, J. 1998. Antibody-mediated thrombosis: Relation to the antiphospholipid syndrome. Lupus, 7, S63–6.Google Scholar
Vila, P., Hernandez, M. C., Lopez-Fernandez, M. E., and Baffle, J. 1994. Prevalence, follow-up and clinical significance of the anticardiolipin antibodies in normal subjects. Thromb Haemost, 72, 209–13.Google Scholar
Wahl, D. G., Guillemin, F., de Maistre, E., et al. 1998. Meta-analysis of the risk of venous thrombosis in individuals with antiphospholipid antibodies without underlying autoimmune disease or previous thrombosis. Lupus, 7, 15–22.Google Scholar
Wang, L., Chen, H., Zhang, Y., et al. 2015. Clinical characteristics of cerebral venous sinus thrombosis in patients with systemic lupus erythematosus: A single-centre experience in China. J Immunol Res, 2015, 1–7.Google Scholar
Zeiger, B., Sepp, N., Stockhammer, G., et al. 1993. Sneddon’s syndrome: A long term follow-up of 21 patients. Arch Dermatol, 129, 437–44.Google Scholar
Ziporen, L. and Shoenfeld, Y. 1998. Antiphospholipid syndrome: From patient’s bedside to experimental animal models and back to the patient’s bedside. Hematol Cell Ther, 40, 175–82.Google Scholar
Zuily, S., Regnault, V., Selton-Sulty, C., et al. 2011. Increased risk for heart valve disease associated with antiphospholipid antibodies in patients with systemic lupus erythematosus: Meta-analysis of echocardiographic studies. Circulation, 124, 215–24.Google Scholar

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×